

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Venrock Healthcare Capital Partners III, L.P.</u> (Last) (First) (Middle) C/O VENROCK 7 BRYANT PARK, 23RD FLOOR (Street) NEW YORK NY 10018 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>KalVista Pharmaceuticals, Inc. [KALV]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/25/2026	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/25/2026		S		174,485	D	\$16.95 ⁽¹⁾	5,129,500 ⁽²⁾	I	By Funds ⁽³⁾
Common Stock	03/25/2026		S		160	D	\$17.53 ⁽⁴⁾	5,129,340 ⁽⁵⁾	I	By Funds ⁽³⁾
Common Stock	03/26/2026		S		21,386	D	\$17.76 ⁽⁶⁾	5,107,954 ⁽⁷⁾	I	By Funds ⁽³⁾
Common Stock	03/26/2026		S		15,417	D	\$18.82 ⁽⁸⁾	5,092,537 ⁽⁹⁾	I	By Funds ⁽³⁾
Common Stock	03/26/2026		S		3,183	D	\$19.12 ⁽¹⁰⁾	5,089,354 ⁽¹¹⁾	I	By Funds ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners III, L.P.
 (Last) (First) (Middle)
 C/O VENROCK
 7 BRYANT PARK, 23RD FLOOR
 (Street)
 NEW YORK NY 10018
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
VHCP Co-Investment Holdings III, LLC

(Last) (First) (Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

NY

10018

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[VHCP Management EG, LLC](#)

(Last) (First) (Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

NY

10018

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[Venrock Healthcare Capital Partners EG, L.P.](#)

(Last) (First) (Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

NY

10018

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[VHCP Management III, LLC](#)

(Last) (First) (Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

NY

10018

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[Koh Bong Y](#)

(Last) (First) (Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

NY

10018

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[Shah Nimish P](#)

(Last) (First) (Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

NY

10018

(City)

(State)

(Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$16.51 to \$17.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
2. Consists of (i) 1,105,126 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,550 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"); and (iii) 3,913,824 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
3. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$17.51 to \$17.55 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
5. Consists of (i) 1,105,092 shares held by VHCP3; (ii) 110,547 shares held by VHCP Co-3; and (iii) 3,913,701 shares held by VHCP EG.
6. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$17.07 to \$18.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
7. Consists of (i) 1,100,485 shares held by VHCP3; (ii) 110,085 shares held by VHCP Co-3; and (iii) 3,897,384 shares held by VHCP EG.
8. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$18.07 to \$19.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
9. Consists of (i) 1,097,164 shares held by VHCP3; (ii) 109,752 shares held by VHCP Co-3; and (iii) 3,885,621 shares held by VHCP EG.
10. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from \$19.07 to \$19.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
11. Consists of (i) 1,096,478 shares held by VHCP3; (ii) 109,684 shares held by VHCP Co-3; and (iii) 3,883,192 shares held by VHCP EG.

Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory 03/27/2026

VHCP Co-Investment Holdings III, LLC, By: VHCP Management III, LLC, Its: Manager, By: /s/ Sherman G. Souther, Authorized Signatory 03/27/2026

VHCP Management III, LLC, By: /s/ Sherman G. Souther, Authorized Signatory 03/27/2026

Venrock Healthcare Capital Partners EG, L.P., By: VHCP Management EG, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory 03/27/2026

VHCP Management EG, LLC, By: /s/ Sherman G. Souther, Authorized Signatory 03/27/2026

Bong Koh, By: /s/ Sherman G. Souther, Attorney-in-fact 03/27/2026

Nimish Shah, By: /s/ Sherman G. Souther, Attorney-in-fact 03/27/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.